Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Burbank, California Clinical Trials

A listing of Burbank, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (1130) clinical trials

Study of Ibrutinib and Rituximab in Treatment Na ve Follicular Lymphoma

The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment nave subjects with follicular lymphoma.

Phase

0.0 miles

Learn More »

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

The purpose of the study is to assess the safety, tolerability and activity of a once-weekly regimen of carfilzomib in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma.

Phase

0.0 miles

Learn More »

A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens. Niraparib is an orally active PARP inhibitor. Niraparib will be administered once daily continuously during a 28-day cycle. Health-related quality ...

Phase

0.0 miles

Learn More »

Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

Ten year safety study examining rates of rare adverse events, child bearing issues, effects of mammography, MRI compliance and results, and long-term benefit of silicone-filled breast implants.

Phase N/A

1.03 miles

Learn More »

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

To test the safety and effectiveness of netarsudil 0.02% and 0.04% ophthalmic solution relative to placebo in Japanese/Japanese-American subjects with elevated intraocular pressure

Phase

1.11 miles

Learn More »

An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

Treatment Period 1 (Progestin Monotherapy): During Treatment Period 1, all subjects determined to be PrR positive will receive progestin monotherapy, megestrol acetate, for up to 24 weeks. Subjects will have an MRI or CT scan after 12 and 24 weeks of progestin monotherapy, with response to treatment being assessed according ...

Phase

2.17 miles

Learn More »

Memory Gel and Shape Combined Cohort

The post-approval study will include 2518 women undergoing breast augmentation or reconstruction with MemoryShape or MemoryGel Breast Implants. Four cohorts will be included: primary augmentation, revision-augmentation, primary reconstruction, and revision-reconstruction. For the purpose of assessing rheumatological and neurological signs and symptoms, a control group of 300 women will be selected ...

Phase N/A

2.17 miles

Learn More »

Open-Label Extension and Safety Study of Talazoparib

This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.

Phase

2.17 miles

Learn More »

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy Surgery and/or Radiation Therapy

This is a randomized double-blind placebo-controlled phase III trial of aspirin (300 mg daily) in early stage node-positive HER2 negative breast cancer patients. Patients will be randomized 1:1 within stratum defined by: Hormone Receptor status (HR positive vs HR negative), body mass index (<30 vs 30 kg/m2) and stage (Stage ...

Phase

2.17 miles

Learn More »

Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF.

Phase

2.17 miles

Learn More »